Why the study?
Do haloperidol, clopenthixol, and chlorpromazine affect EEG measures compared to placebo in chronic schizophrenic patients?
Do haloperidol, clopenthixol, and chlorpromazine affect EEG measures compared to placebo in chronic schizophrenic patients?
Haloperidol, clopenthixol, and chlorpromazine produce similar overall EEG changes in chronic schizophrenic patients, reflecting their similar clinical effectiveness.
Comparable EEG effects support clinical interchangeability among these antipsychotics; extends validation of EEG as a biomarker for antipsychotic response.
Electroencephalographic (EEG) studies were conducted in 40 chronic schizophrenic men and women participating in a 3-month haloperidol (HAL), clopenthixol (CX), and chlorpromazine (CPZ) double blind placebo-controlled study. Of these 40 patients, 13 were on HAL, 9 on CX, 8 on CPZ, and 10 on placebo (PL). Despite some suggestive differences, the overall EEG measures of these drugs were similar, paralleling in this respect their similarity in overall clinical effectiveness despite their chemical differences.
No takes yet. Share an insight, caveat, or question.
Serafetinides et al. (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: